Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
DVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.20 - $14.63
Previous CloseN/A
Volume272.71K
Average Volume (3M)1.85M
Market Cap
$1.10B
Enterprise Value$1.05B
Total Cash (Recent Filing)$613.73M
Total Debt (Recent Filing)$285.50M
Price to Earnings (P/E)64.5
Beta0.27
Next Earnings
Oct 30, 2025EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding117,267,480
10 Day Avg. Volume1,779,408
30 Day Avg. Volume1,845,845
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.31
Enterprise Value/Gross Profit4.00
Enterprise Value/Ebitda-30.33
Forecast
1Y Price Target
$22.67Price Target Upside133.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageThe promising initial results with Z-1018 warrant more attention as a viable second asset for the company in a multi-blockbuster indication.
Product DevelopmentThe immunogenicity of the Z-1018 vaccine candidate exceeded initial expectations, showing strong vaccine response rates.
Revenue GrowthHeplisav's strong market share in the dialysis channel supports continued strong uptake and revenue growth.
Bears Say
Market ShareMarket share in the prioritized IDN/clinic market segment showed a slight reduction at 51%.
Dynavax News
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $9.20 and its highest was $14.63 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Dynavax Technologies Corp.’s market cap is $1.10B.
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is Oct 30, 2025 which is in 42 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Aug 07, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.105 by $0.035.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is 0.13.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 117,267,480 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0.14 in its last earnings report, beating expectations of $0.105. Following the earnings report the stock price went down -6.6%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Currently, no hedge funds are holding shares in DVAX
Dynavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.67 (133.71% Upside)
$22.67 (133.71% Upside)
Blogger Sentiment
Bullish
DVAX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 5.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $22.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.20%
12-Months-Change
Fundamentals
Return on Equity
-9.28%
Trailing 12-Months
Asset Growth
-9.63%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
DVAX Company Deck
DVAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record-breaking revenue and increased market share for HEPLISAV-B, along with positive updates in the vaccine pipeline and strategic financial decisions. However, there were challenges such as increased SG&A expenses and a reduction in cash reserves. Overall, the positive aspects significantly outweigh the negatives.View all DVAX earnings summariesDVAX Stock 12 Month Forecast
Average Price Target
$22.67
▲(133.71% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Collegium Pharmaceutical
―
Ownership Overview
13.93% Insiders
17.95% Mutual Funds
31.55% Other Institutional Investors
12.70% Public Companies and
Individual Investors